title: [Mantle cell lymphoma as a diagnostic and therapeutic problem].
abstract: The authors present the characteristics of a group of 23 patients with mantle cell lymphoma. In the group only a slight predominance of men over women was found (1.1:1), the median age was 63 years. Twenty-one (91%) of the patients were diagnosed in stage IV (Ann Arbor). In all these patients the bone marrow was affected. In 19 of them immunoflowcytometric analysis revealed the typical clone of B lymphocytes (CD5 positive)/CD 23 negative). The majority of patients had at the time of diagnosis a large tumourous mass with massive splenomegaly (61%), hepatomegaly (57%) and bulky disease (52%). The node was excised in 17 patients, but in four patients (24%) during the first session the diagnosis was not assessed correctly. In the laboratory findings an inclination to anaemia, thrombocytopenia, lymphocytosis and in particular to high levels of serological indicators of activity of the disease dominated--lactate dehydrogenase, beta-2-microglobulin and serum thymidine kinase. All patients were treated by chemotherapy. Complete remission was achieved by the date of evaluation in one patient (4%), partial remission in seven patients (30%) but 48% patients did not respond to first line treatment. Nine patients of the group died, their median of survival was 14 months (0-24), the median of the follow up of the remaining patients was 133 months (2-31). Two female patients had large-dose treatment with subsequent administration of autologous stem cells. The first one is after 370 days of treatment in complete remission, the second one developed a relapse 100 days after the procedure. From the results and analysis of the literature ensues that mantle cell lymphoma is one of the aggressive malignant B-lymphoproliferations with a very adverse prognosis and it deserves therefore special diagnostic and intense therapeutic attention.
authors.affiliation: Hemato-onkologická klinika FN, Olomouc.
authors.forename: T
authors.initials: T
authors.lastname: Papajík
authors.forename: L
authors.initials: L
authors.lastname: Raida
authors.forename: E
authors.initials: E
authors.lastname: Faber
authors.forename: J
authors.initials: J
authors.lastname: Hubácek
authors.forename: M
authors.initials: M
authors.lastname: Heczko
authors.forename: P
authors.initials: P
authors.lastname: Slezák
authors.forename: I
authors.initials: I
authors.lastname: Sulovská
authors.forename: Z
authors.initials: Z
authors.lastname: Pikalová
authors.forename: E
authors.initials: E
authors.lastname: Kynclová
authors.forename: J
authors.initials: J
authors.lastname: Dusek
authors.forename: M
authors.initials: M
authors.lastname: Tichý
authors.forename: M
authors.initials: M
authors.lastname: Jarosová
authors.forename: K
authors.initials: K
authors.lastname: Indrák
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate
vernacular_title: Mantle cell lymfom jako diagnostický a lécebný problém.